Jerini AG (DE) - Ad hoc: Jerini AG to Wind Down its Preclinical Programs

Berlin, June 26, 2009 - Jerini AG has decided to end all negotiations regarding the transfer of assets associated with Jerini AG's preclinical programs and to terminate the employees associated with these programs. The decision was taken following unsuccessful efforts to find an investor for the sale of the preclinical programs. The redundancies reduce Jerini AG's head-count by more than 45.

Jerini AG The Management Board

ISIN: DE0006787476 WKN: 678 747 Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany Registered Office: Berlin, Germany

For questions, please contact: Stacy Wiedenmann Director Investor Relations & Corporate Communications Jerini AG Invalidenstr. 130 10115 Berlin T + 49 - 30 - 97893 - 285 X + 49 - 30 - 97893 - 599 wiedenmann@jerini.

Posted: June 2009


View comments

Hide
(web4)